View Past PerformanceCypherpunk Technologies バランスシートの健全性財務の健全性 基準チェック /66Cypherpunk Technologiesの総株主資本は$153.5M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$163.2Mと$9.7Mです。主要情報0%負債資本比率US$0負債インタレスト・カバレッジ・レシオn/a現金US$14.04mエクイティUS$153.51m負債合計US$9.68m総資産US$163.18m財務の健全性に関する最新情報Cypherpunk Technologies Inc. Receives Notification Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketMar 10Nasdaq Grants Leap Therapeutics, Inc. Extension to Regain Compliance with Minimum Bid Price RequirementSep 12Leap Therapeutics Receives Nasdaq Closing Bid Price Deficiency LetterMar 18Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share RequirementsJun 21Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?Mar 13Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?Nov 22すべての更新を表示Recent updatesCypherpunk Technologies Inc., Annual General Meeting, Jun 18, 2026May 02Investor sentiment improves as stock rises 39% Apr 10Cypherpunk Technologies Inc. Receives Notification Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketMar 10New major risk - Revenue and earnings growth Nov 19Leap Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.Nov 13Cypherpunk Technologies Inc. Announces Management ChangesNov 12Leap Therapeutics, Inc. Presents Final Data from DeFianCe Study at ESMO 2025Oct 21New major risk - Shareholder dilution Oct 14Leap Therapeutics, Inc. announced that it has received $49.890683 million in funding from Winklevoss Capital Management LLC and other investorsOct 09Leap Therapeutics, Inc. announced that it expects to receive $58.888888 million in fundingOct 07New major risk - Share price stability Oct 02Nasdaq Grants Leap Therapeutics, Inc. Extension to Regain Compliance with Minimum Bid Price RequirementSep 12Leap Therapeutics, Inc. Announces Executive ChangesJun 25Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic AlternativesJun 24Insufficient new directors Jun 20Leap Therapeutics, Inc., Annual General Meeting, Jun 18, 2025Apr 29Leap Therapeutics, Inc. to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, At the AACR 2025 Annual MeetingApr 26Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer StudyMar 26Leap Therapeutics Receives Nasdaq Closing Bid Price Deficiency LetterMar 18Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish StudyJan 28Leap Therapeutics, Inc. Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer PatientsOct 01Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024May 01Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LPApr 12Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers SymposiumJan 17Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer PatientsJan 02Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer PatientsJul 13Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share RequirementsJun 21Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual MeetingMay 26Price target decreased by 10.0% to US$2.70 Mar 26Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?Mar 13Leap Therapeutics, Inc. (NasdaqGM:LPTX) acquired Flame Biosciences, Inc from Acuta Capital Partners LLC, Adage Capital Management, L.P., Cormorant Asset Management, LP, Cormorant Asset Management, LP, Terra Magnum Capital Partners and others.Jan 19Price target decreased to US$3.60 Jan 19Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of DirectorsJan 18Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?Nov 22Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021) Nov 16First half 2022 earnings released Aug 12Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05 Aug 12Price target decreased to US$4.40 Jul 13Leap Therapeutics begins trials of DKN-01 in gastric/colorectal cancers Jul 12Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022 Jun 27Consensus forecasts updated Jun 01Consensus revenue estimates increase by 99% May 20First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 13Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn SituationMay 01Insufficient new directors Apr 27Full year 2021 earnings: EPS and revenues miss analyst expectations Mar 13Leap Therapeutics: Waiting For One More Leap Feb 18We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash WiselyJan 04Insufficient new directors Jan 03Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company? Nov 29Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.092 loss in 3Q 2020) Nov 14Leap Therapeutics: All On The Line Oct 13Price target increased to US$4.50 Sep 21Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?Sep 15Price target decreased to US$4.00 Aug 31First half 2021 earnings released: US$0.24 loss per share (vs US$0.57 loss in 1H 2020) Aug 18Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?Jun 01Consensus forecasts updated May 21Consensus forecasts updated Mar 19Revenue and earnings miss expectations Mar 14Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In GrowthMar 03New 90-day high: US$2.63 Feb 06Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?Jan 27New 90-day high: US$2.42 Jan 20Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last YearDec 23New 90-day high: US$2.37 Dec 22Analysts update estimates Nov 19Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)Nov 18Revenue beats expectations, earnings disappoint Nov 13New 90-day low: US$1.53 Nov 10New 90-day high: US$2.19 Oct 16財務状況分析短期負債: CYPHの 短期資産 ( $162.1M ) が 短期負債 ( $4.6M ) を超えています。長期負債: CYPHの短期資産 ( $162.1M ) が 長期負債 ( $5.1M ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: CYPHは負債がありません。負債の削減: CYPH 5 年前には負債がありませんでした。債務返済能力: CYPHには負債がないため、営業キャッシュフロー でカバーする必要はありません。インタレストカバレッジ: CYPHには負債がないため、利息支払い の負担は問題になりません。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2026/05/01 11:40終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cypherpunk Technologies Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Swayampakula RamakanthH.C. Wainwright & Co.Wangzhi LiLadenburg Thalmann & CompanyTyler Van BurenPiper Sandler Companies1 その他のアナリストを表示
Cypherpunk Technologies Inc. Receives Notification Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketMar 10
Nasdaq Grants Leap Therapeutics, Inc. Extension to Regain Compliance with Minimum Bid Price RequirementSep 12
Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share RequirementsJun 21
Cypherpunk Technologies Inc. Receives Notification Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketMar 10
Leap Therapeutics, Inc. announced that it has received $49.890683 million in funding from Winklevoss Capital Management LLC and other investorsOct 09
Nasdaq Grants Leap Therapeutics, Inc. Extension to Regain Compliance with Minimum Bid Price RequirementSep 12
Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic AlternativesJun 24
Leap Therapeutics, Inc. to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, At the AACR 2025 Annual MeetingApr 26
Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish StudyJan 28
Leap Therapeutics, Inc. Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer PatientsOct 01
Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LPApr 12
Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers SymposiumJan 17
Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer PatientsJan 02
Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer PatientsJul 13
Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share RequirementsJun 21
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual MeetingMay 26
Leap Therapeutics, Inc. (NasdaqGM:LPTX) acquired Flame Biosciences, Inc from Acuta Capital Partners LLC, Adage Capital Management, L.P., Cormorant Asset Management, LP, Cormorant Asset Management, LP, Terra Magnum Capital Partners and others.Jan 19
Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last YearDec 23